CPC A61K 47/14 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 9/127 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61P 17/06 (2018.01)] | 18 Claims |
1. A method of treating a dermatological or mucosal disorder or condition, the method comprising topically administering a pharmaceutical composition comprising a corticosteroid to the skin of an individual having the dermatological or mucosal disorder or condition, wherein the pharmaceutical composition comprises:
a liquid oil component comprising one or more monocarboxylic acid esters and/or dicarboxylic acid esters, and mineral oil, light mineral oil, or a combination thereof, and
a corticosteroid at a concentration of about 0.01% to about 0.030% or less, and wherein at least 25% of the corticosteroid is solubilized in the liquid oil component at a temperature of 22° C.+/−2° C.; and
an aqueous component comprising water;
wherein the corticosteroid is selected from the group consisting of clobetasol propionate, betamethasone dipropionate, halobetasol propionate, diflorasone diacetate, desoximetasone, mometasone furoate, betamethasone valerate, halcinonide, budesonide, fluocinonide, and amcinonide; and
wherein the pharmaceutical composition is free of white petrolatum;
wherein the pharmaceutical composition is formulated as a lotion or a cream.
|